中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2015年
15期
2887-2891
,共5页
谢林艳%柏芳芳%陈子%周林福
謝林豔%柏芳芳%陳子%週林福
사림염%백방방%진자%주림복
哮喘%白细胞介素4%白细胞介素13%嗜酸粒细胞%Dupilumab
哮喘%白細胞介素4%白細胞介素13%嗜痠粒細胞%Dupilumab
효천%백세포개소4%백세포개소13%기산립세포%Dupilumab
Asthma%Interleukin-4%Interleukin-13%Eosinophils%Dupilumab
支气管哮喘是一种以Th2优势免疫为特征的气道过敏性疾病,其中嗜酸粒细胞性气道炎症、气道高反应性和气道重塑为哮喘三个主要的临床特征。Dupilumab 是抗 IL-4受体α亚基(IL-4Rα)的单抗,能抑制IL-4Rα与IL-4和IL-13结合并阻断其介导的下游信号转导,从而抑制哮喘气道炎症、气道高反应性和气道重塑的发生发展。本文将就Dupilumab治疗嗜酸粒细胞增高的中重度持续性哮喘的研究进展作一综述。
支氣管哮喘是一種以Th2優勢免疫為特徵的氣道過敏性疾病,其中嗜痠粒細胞性氣道炎癥、氣道高反應性和氣道重塑為哮喘三箇主要的臨床特徵。Dupilumab 是抗 IL-4受體α亞基(IL-4Rα)的單抗,能抑製IL-4Rα與IL-4和IL-13結閤併阻斷其介導的下遊信號轉導,從而抑製哮喘氣道炎癥、氣道高反應性和氣道重塑的髮生髮展。本文將就Dupilumab治療嗜痠粒細胞增高的中重度持續性哮喘的研究進展作一綜述。
지기관효천시일충이Th2우세면역위특정적기도과민성질병,기중기산립세포성기도염증、기도고반응성화기도중소위효천삼개주요적림상특정。Dupilumab 시항 IL-4수체α아기(IL-4Rα)적단항,능억제IL-4Rα여IL-4화IL-13결합병조단기개도적하유신호전도,종이억제효천기도염증、기도고반응성화기도중소적발생발전。본문장취Dupilumab치료기산립세포증고적중중도지속성효천적연구진전작일종술。
Bronchial asthma is a Th2 immunity-dominated common airway allergic disease, characterized by eosinophilic airway inflammation, airway hyperresponsiveness and airway remodeling. Dupilumab,a novel monoclonal antibody targeting the α-subunit of IL-4 receptor (IL-4Rα), is capable of binding with IL-4Rα to block both IL-4 and IL-13-mediated signaling pathways, leading to inhibit the airway inflammation, hyperresponsiveness and remodeling. This paper focused on the progress of Dupilumab in persistent moderate-to-severe asthma with elevated eosinophil levels.